Ascendis Pharma A (ASND) EBT Margin Growth (5y) (2019 - 2026)
Analysis
Ascendis Pharma A (ASND) EBT Margin Growth (5y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ascendis Pharma A | 16.39 Bn | 15.45 Bn | 362.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.32 Mn |
| Mar 31, 2026 | 842,322.00 |
| Dec 31, 2025 | 19,031.00 |
| Sep 30, 2025 | 438,954.00 |
| Jun 30, 2025 | 659,610.00 |
| Mar 31, 2025 | 275,649.00 |
| Dec 31, 2024 | 17,728.00 |
| Sep 30, 2024 | 95,257.00 |
| Jun 30, 2024 | 153,325.00 |
| Mar 31, 2024 | 85,797.00 |
| Dec 31, 2023 | 6,492.00 |
| Sep 30, 2023 | 17.00 Mn |
| Jun 30, 2023 | 12.68 Mn |
| Mar 31, 2023 | 14.78 Mn |
| Dec 31, 2022 | 1.14 Mn |
| Sep 30, 2022 | 675,496.00 |
| Jun 30, 2022 | 560,322.00 |
| Mar 31, 2022 | 492,710.00 |
| Dec 31, 2021 | 145,161.00 |
| Sep 30, 2021 | -565,222.00 |